NASDAQ : ETRA
Electra Therapeutics, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 8.1 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 508.41M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Selling, General & Admin | 13.52M | 11.50M | 7.05M |
| Research & Development | 73.23M | 50.39M | 19.27M |
| Operating Expenses | 86.75M | 61.89M | 26.32M |
| Operating Income | -86.75M | -61.89M | -26.32M |
| Interest Expense | -1.11M | -1.43M | |
| Interest & Investment Income | 2.35M | 1.36M | 1.52M |
| Currency Exchange Gain (Loss) | -15.00K | -15.00K | 7.00K |
| Pretax Income | -85.53M | -61.98M | -24.79M |
| Net Income | -85.53M | -61.98M | -24.79M |
| Net Income to Common | -95.20M | -61.98M | -24.79M |
| Shares Outstanding (Basic) | 44.00K | 44.00K | 44.00K |
| Shares Outstanding (Diluted) | 44.00K | 44.00K | 44.00K |
| EPS (Basic) | -2,163.66 | -1,408.52 | -563.32 |
| EPS (Diluted) | -2,163.66 | -1,408.52 | -563.32 |
| Free Cash Flow | -75.32M | -61.22M | -26.00M |
| Free Cash Flow Per Share | -1,711.80 | -1,391.30 | -590.98 |
| EBITDA | -61.83M | ||
| D&A For EBITDA | 61.00K | ||
| EBIT | -86.75M | -61.89M | -26.32M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Cash & Equivalents | 66.51M | 33.01M | 14.79M |
| Short-Term Investments | 31.22M | 53.51M | 998.00K |
| Cash & Short-Term Investments | 97.72M | 86.52M | 15.79M |
| Other Receivables | 264.00K | 220.00K | 55.00K |
| Receivables | 264.00K | 220.00K | 55.00K |
| Prepaid Expenses | 1.98M | 8.57M | 3.42M |
| Other Current Assets | 392.00K | 179.00K | 165.00K |
| Total Current Assets | 100.36M | 95.49M | 19.42M |
| Property, Plant & Equipment | 2.41M | 2.78M | |
| Other Long-Term Assets | 1.83M | 1.10M | |
| Total Assets | 106.50M | 99.37M | 19.42M |
| Accounts Payable | 4.61M | 4.08M | 1.53M |
| Accrued Expenses | 8.19M | 5.04M | 2.66M |
| Current Portion of Leases | 827.00K | 605.00K | |
| Total Current Liabilities | 13.63M | 9.73M | 4.20M |
| Long-Term Leases | 1.16M | 1.48M | |
| Total Liabilities | 14.78M | 11.21M | 4.20M |
| Additional Paid-In Capital | 2.45M | 9.52M | 7.74M |
| Retained Earnings | -221.89M | -172.98M | -111.00M |
| Comprehensive Income & Other | -13.00K | 21.00K | 1.00K |
| Total Common Equity | -219.46M | -163.44M | -103.26M |
| Shareholders' Equity | 91.72M | 88.16M | 15.22M |
| Total Liabilities & Equity | 106.50M | 99.37M | 19.42M |
| Total Debt | 1.98M | 2.09M | |
| Net Cash (Debt) | 95.74M | 84.43M | 15.79M |
| Net Cash Per Share | 2,175.95 | 1,918.89 | 358.75 |
| Filing Date Shares Outstanding | 61.10M | 44.00K | 44.00K |
| Total Common Shares Outstanding | 44.00K | 44.00K | 44.00K |
| Working Capital | 86.73M | 85.76M | 15.22M |
| Book Value Per Share | -4,987.61 | -3,714.59 | -2,346.84 |
| Tangible Book Value | -219.46M | -163.44M | -103.26M |
| Tangible Book Value Per Share | -4,987.61 | -3,714.59 | -2,346.84 |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Net Income | -85.53M | -61.98M | -24.79M |
| Depreciation & Amortization | 183.00K | 61.00K | |
| Loss (Gain) From Sale of Investments | -788.00K | -248.00K | -722.00K |
| Stock-Based Compensation | 3.48M | 1.77M | 2.31M |
| Other Operating Activities | 1.60M | 1.65M | |
| Change in Accounts Receivable | -222.00K | -165.00K | 38.00K |
| Change in Accounts Payable | -160.00K | 2.54M | 98.00K |
| Change in Other Net Operating Assets | 6.76M | -4.12M | -2.94M |
| Operating Cash Flow | -74.67M | -60.48M | -26.00M |
| Capital Expenditures | -644.00K | -733.00K | |
| Investment in Securities | -30.44M | -52.24M | 29.70M |
| Investing Cash Flow | -31.09M | -52.98M | 29.70M |
| Short-Term Debt Issued | 40.00M | ||
| Total Debt Issued | 40.00M | ||
| Net Debt Issued (Repaid) | 40.00M | ||
| Other Financing Activities | -1.49M | -1.10M | |
| Financing Cash Flow | 141.29M | 131.68M | |
| Net Cash Flow | 35.53M | 18.22M | 3.70M |
| Free Cash Flow | -75.32M | -61.22M | -26.00M |
| Free Cash Flow Per Share | -1,711.80 | -1,391.30 | -590.98 |
| Levered Free Cash Flow | -38.88M | ||
| Unlevered Free Cash Flow | -37.99M | ||
| Cash Income Tax Paid | 13.00K | 8.00K | 27.00K |
| Change in Working Capital | 6.38M | -1.74M | -2.80M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Market Capitalization | 508.41M | ||
| Enterprise Value | 412.67M | ||
| Debt / Equity Ratio | 0.02 | 0.02 | |
| Net Debt / Equity Ratio | -1.04 | -0.96 | -1.04 |
| Net Debt / EBITDA Ratio | 1.37 | ||
| Net Debt / FCF Ratio | 1.27 | 1.38 | 0.61 |
| Quick Ratio | 7.19 | 8.92 | 3.78 |
| Current Ratio | 7.37 | 9.82 | 4.63 |
| Return on Equity (ROE) | -119.89% | ||
| Return on Assets (ROA) | -65.12% | ||
| Return on Capital Employed (ROCE) | -93.40% | -69.00% | -172.90% |